A critical look at phenytoin use for early post-traumatic seizure prophylaxis

Sierra Debenham1, Behzad Sabit, Rajeet S Saluja

  • 1Bringham Young University, Provo, Utah, USA.

Insights

Phenytoin prophylaxis effectively prevents early post-traumatic seizures (PTS) in traumatic brain injury (TBI) patients with rare side effects. Earlier administration and optimized drug levels could further improve seizure prevention in TBI care.

Area of Science:

  • Neurology
  • Trauma Care

Background:

  • The American Academy of Neurology recommends phenytoin or carbamazepine for preventing early post-traumatic seizures (PTS) in severe traumatic brain injuries (TBI).
  • Limited data exists on the compliance and side effects of systematic phenytoin use in large populations across TBI severity levels.
  • This study investigates phenytoin prophylaxis in mild, moderate, and severe TBI cases.

Purpose of the Study:

  • Determine the proportion of TBI patients receiving phenytoin prophylaxis.
  • Identify parameters influencing phenytoin administration decisions.
  • Evaluate the efficacy and complication rates of phenytoin prophylaxis.

Main Methods:

  • Retrospective study of 1008 patients admitted with TBI over two years.
  • Collected data included age, GCS score, CT-scan Marshall grade, PTS incidence, phenytoin use, administration delay, side effects, and dosage accuracy.
  • Analysis focused on prophylaxis rates, decision-making factors, efficacy, and complications.

Main Results:

  • 5.4% of patients experienced early PTS; 2.3% while on prophylaxis.
  • Phenytoin prophylaxis was administered to 64.8% of patients, with positive CT scans being the primary decision factor (p<.001).
  • Compliance with guidelines was high (99.7%), with rare adverse reactions (0.5%).

Conclusions:

  • Phenytoin is utilized in accordance with guidelines for TBI patients, primarily guided by CT scan findings.
  • The incidence of early PTS is low, and side effects associated with phenytoin are infrequent.
  • Earlier phenytoin administration and achieving adequate therapeutic levels may further enhance the prevention of early PTS in TBI.
Abstract

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...